Data Sharing Solutions for Biobanks for the COVID-19 Pandemic

被引:7
作者
Paul, Shonali [1 ]
Chatterjee, Mrinal Kanti [1 ]
机构
[1] CloudLIMScom, 831 N Tatnall St,Suite M 118, Wilmington, DC 19801 USA
关键词
COVID-19; testing; COVID-19 diagnostic testing; specimens; LIMS; biobanks;
D O I
10.1089/bio.2020.0040
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The coronavirus disease 2019 (COVID-19) is a novel illness, which is not fully understood. Whether an individual has traveled outside their respective country or never left their community, COVID-19 is a highly contagious illness, which can result in high death rates. Biobanks will play a role in providing tools to examine data from those receiving treatment along with reviewing the current and long treatment outcomes associated with this novel coronavirus disease. A diverse, global network made up of laboratory scientists, clinical researchers, epidemiologists, data science teams, physicians, and so on must have a standardized, collaborative, virtual biobanking solution to share clinical expertise and evidence-based solutions. This virtual biobank must be centrally managed to ensure standardized quality assurance and quality control efforts. Virtual biobanks will eliminate the need to transport samples between two locations for a specific study, minimizing the risk of contamination. It is necessary for virtual biobanks to upload imaging data from those patients diagnosed with COVID-19. Standardized, collected information will be essential in the area of discovery and validation of disease markers as well as novel therapeutic strategies. It is essential for biobanks to collect COVID-19 specimens along with corresponding clinical and demographic data from COVID-19 diagnostic testing. Because COVID-19 is an acute respiratory illness, proper collection procedures must be in place to collect respiratory samples for biobanking purposes. A preconfigured purpose-built COVID-19 Laboratory Information Management System (LIMS) is an efficient tool to seamlessly manage a data sharing network. Data entered into LIMS will be beneficial in designing much needed clinical trials to address any unmet needs to better address clinical treatment and outcomes. The partners or entities associated with the COVID-19 data sharing network will be able to effectively communicate, view data, and images associated with their respective research interest to advance COVID-19 research and data driven, clinical care.
引用
收藏
页码:581 / 586
页数:6
相关论文
共 16 条
  • [11] Virtual global biorepository: access for all to speed-up result-oriented research
    Kumar, Awanish
    [J]. CELL AND TISSUE BANKING, 2020, 21 (03) : 361 - 365
  • [12] Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management
    Li, Yan
    Xia, Liming
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2020, 214 (06) : 1280 - 1286
  • [13] Challenges and Driving Forces for Business Plans in Biobanking
    Macheiner, Tanja
    Huppertz, Berthold
    Bayer, Michaela
    Sargsyan, Karine
    [J]. BIOPRESERVATION AND BIOBANKING, 2017, 15 (02) : 121 - 125
  • [14] Policies and actions to tackle rare diseases at European level
    Montserrat, Antoni
    Taruscio, Domenica
    [J]. ANNALI DELL ISTITUTO SUPERIORE DI SANITA, 2019, 55 (03): : 296 - 304
  • [15] Paul S, 2020, ISBER BEST PRACTICES
  • [16] Assessing Researcher Needs for a Virtual Biobank
    van Draanen, Jenna
    Davidson, Pamela
    Bour-Jordan, Helene
    Bowman-Carpio, LeeAnna
    Boyle, David
    Dubinett, Steve
    Gardner, Brian
    Gardner, Jachael
    McFall, Courtney
    Mercola, Dan
    Nakazono, Terry
    Soares, Stephanie
    Stoppler, Hubert
    Tempero, Margaret
    Vandenberg, Scott
    Wan, Yu Jui
    Dry, Sarah
    [J]. BIOPRESERVATION AND BIOBANKING, 2017, 15 (03) : 203 - 210